Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab
Clinical trial NCT03612791 · COMPLETED
Trial details
- NCT number
- NCT03612791
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-08-13
- Primary completion
- 2024-02-26
- Enrollment
- 189
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.